Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 28, 2021 at 02:11 pm IST
Share
Kunming Longjin Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 593.81 million compared to CNY 164.38 million a year ago. Revenue was CNY 593.81 million compared to CNY 164.38 million a year ago. Net income was CNY 6.57 million compared to CNY 2.28 million a year ago. Basic earnings per share from continuing operations was CNY 0.0164 compared to CNY 0.0057 a year ago. Diluted earnings per share from continuing operations was CNY 0.0164 compared to CNY 0.0057 a year ago.
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.